Novartis meningitis vaccine used at 2nd US campus

(AP)—Swiss drug maker Novartis says a second U.S. university is using its new vaccine against meningitis B.

Novartis said Monday that the , Bexsero, is being used at the University of California Santa Barbara until March 7 to help protect 20,000 students and staff after an .

The vaccine shot for the B strain of the meningitis bacteria is approved for use in Europe, Australia and Canada, but not yet for general use in the United States.

But the U.S. Food and Drug Administration has now approved the use of Bexsero twice in response to outbreaks at U.S. college campuses. It is the first vaccine against the B strain of meningitis.

Princeton University says almost 5,300 people got the vaccine last year in an effort to halt an outbreak there.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Princeton vaccine reaches 90 percent of eligible

Dec 13, 2013

Princeton University officials say more than 90 percent of the eligible students and staff received a meningitis vaccine this week as part of the university's effort to halt an outbreak.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

12 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments